



BÖLÜM 10

KÜME BAŞ AĞRISI

Merve ÖNERLİ YENER¹

GİRİŞ

Küme baş ağrısı (KBA); orbital, supraorbital veya temporal bölgede tek taraflı, ısrarcı ve dayanılmaz ağrı atakları ve ipsilateral kranial otonomik bulgular ile karakterize bir primer baş ağrısı sendromudur (1,2).

İlk tanımlamanın 17. yüzyılda ünlü doktor ve anatomist Nicolaes Tulp tarafından yapıldığı kabul edilmektedir (3). Yıllar içinde küme tipi Baş ağrısı için Horton hastalığı, migrenöz nevralji gibi birçok farklı isim kullanılmış olup KBA adı ilk olarak 1947 yılında sendromun tipik epizodik karakterini ifade etmek için kullanılmıştır (4). KBA nadir görülen bir hastalıktır, prevalansı 1000 kişide 1 civarındadır; ancak ataklar sırasında dizabilité çok belirgindir. Erkek kadın oranı ise 4.3:1 olarak değerlendirilmektedir (5,6).

KLİNİK ÖZELLİKLER

KBA, trigeminal otonomik sefaljilerin (TOS) en sık görülen tipidir ve insanların daki en şiddetli ağrı sendromlarından biri olarak kabul edilmektedir. Ağrının şiddetini ifade etmek için “intihar baş ağrısı” tanımlaması sıkça kullanılmaktadır (7). Hastalığın tipik başlangıç yaşı 20-40 yaş civarıdır; ancak hemen hemen her yaşıda ortaya çıkabilir. Orbital ve supraorbital bölgelerde belirgin,

¹ Uzm. Dr., Ankara Bilkent Şehir Hastanesi, onerlimerve@gmail.com



KAYNAKLAR

1. Robbins MS, Nahas SJ. Cluster Headache and Other Trigeminal Autonomic Cephalgias. *Contin Lifelong Learn Neurol.* 2021;27(3):633–51.
2. Edvardsson B. Symptomatic cluster headache: A review of 63 cases. SpringerPlus. 2014;3(1):1–8.
3. Gordon N. History of cluster headache. *Curr Pain Headache Rep.* 2005;9(2):132–4.
4. Ekbom, K.A. (1947), Ergotamine tartrate orally in Horton's "histaminic cephalgia" (also called Harris's "ciliary neuralgia"): a new method of treatment. *Acta Psychiatrica Scandinavica*, 22: 105-113.
5. Russell MB. Epidemiology and genetics of cluster headache. *Lancet Neurol.* 2004;3(5):279–83.
6. Fischer M, Marziniak M, Gralow I, Evers S. The incidence and prevalence of cluster headache: A meta-analysis of population-based studies. *Cephalgia.* 2008;28(6):614–8.
7. Hoffmann J, May A. Diagnosis, pathophysiology, and management of cluster headache. *Lancet Neurol.* 2018;17(1):75–83.
8. Issi Z, Ad N, Ad N. Küme Baş Ağrısı. *Türkiye Klinikleri J Neurol-Special Topics* 2018;11:66–73.
9. Wilbrink LA, Louter MA, Teernstra OPM, et al. Allodynia in cluster headache. *Pain.* 2017;158(6):1113–7.
10. de Coo IF, Wilbrink LA, le GD, et al. Aura in Cluster Headache: A Cross-Sectional Study. *Headache.* 2018;58(8):1203–10.
11. Weaver-Agostoni J. Cluster headache. *Am Fam Physician.* 2013;88(2):122–8.
12. Schürks M, Diener HC. Cluster headache and lifestyle habits. *Curr Pain Headache Rep.* 2008;12(2):115–21.
13. Nesbitt AD, Goadsby PJ. Cluster headache. *BMJ.* 2012;344(7852):1–9.
14. Goadsby PJ. Pathophysiology of cluster headache: A trigeminal autonomic cephalgia. *Lancet Neurol.* 2002;1(4):251–7.
15. Ashina M, Geppetti P. (2015) *Pathophysiology of Headaches.* 70–77 p. Springer.
16. Buture A, Boland JW, Dikomitis L, et al. Update on the pathophysiology of cluster headache: Imaging and neuropeptide studies. *J Pain Res.* 2019;12:269–81.
17. Goadsby PJ. Autonomic nervous system control of the cerebral circulation. *Handb Clin Neurol.* 2013;117:193–201.
18. T. Sprenger, H. Boecker, T. R. Tolle, et al. *Neurology* Feb 2004, 62 (3) 516-517.
19. May A, Bahra A, Büchel C, et al. Hypothalamic activation in cluster headache attacks. *Lancet.* 1998;352(9124):275–8.
20. Coomans CP, Ramkisoens A, Meijer JH. The suprachiasmatic nuclei as a seasonal clock. *Front Neuroendocrinol.* 2015;37:29–42.
21. Li C, Fitzgerald MEC, Ledoux MS, et al. Projections from the hypothalamic paraventricular nucleus and the nucleus of the solitary tract to prechoroidal neurons in the superior salivatory nucleus: Pathways controlling rodent choroidal blood flow. *Brain Res.* 2010;1358:123–39.
22. Olesen J. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. *Cephalgia.* 2018;38(1):1–211.
23. Diamond S, Urban G. Cluster Headache. *Pain Manag.* 2006;1:474–91.
24. Vollesen AL, Benemei S, Cortese F, et al. Migraine and cluster headache - the common



- link. *J Headache Pain.* 2018;19(1):89.
- 25. Burish MJ, Rozen TD. Trigeminal Autonomic Cephalgias. *Neurol Clin.* 2019;37(4):847–69.
 - 26. Simms HN, Honey CR. The importance of autonomic symptoms in trigeminal neuralgia. *Journal of Neurosurgery JNS.* 2011;115(2):210–6.
 - 27. Mainardi F, Trucco M, Maggioni F, et al. Cluster-like headache. A comprehensive reappraisal. *Cephalgia.* 2010;30(4):399–412.
 - 28. Fagan L. Treatment of Cluster Headache: A Double-blind Comparison of Oxygen v Air Inhalation. *Arch Neurol.* 1985;42(4):362–3.
 - 29. Taylor FR. High-flow oxygen for treatment of cluster headache: A randomized trial. *Headache.* 2010;50(4):680–1.
 - 30. Ekbom K, Monstad I, Prusinski A, et al. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. *Acta Neurol Scand.* 1993;88(1):63–9.
 - 31. Cittadini E, May A, Straube A, et al. Effectiveness of Intransal Zolmitriptan in Acute Cluster Headache. *Arch Neurol.* 2006;63(11):1537.
 - 32. Van Vliet JA, Bahra A, Martin V, et al. Intransal sumatriptan in cluster headache: Randomized placebo-controlled double-blind study. *Neurology.* 2003;60(4):630–3.
 - 33. Bahra A, Gawel MJ, Hardebo JE, et al. Oral zolmitriptan is effective in the acute treatment of cluster headache. *Neurology.* 2000;54(9):1832–9.
 - 34. Robbins L. Intransal Lidocaine for Cluster Headache. *Headache J Head Face Pain.* 1995;35(2):83–4.
 - 35. Costa A, Pucci E, Antonaci F, et al. The effect of intransal cocaine and lidocaine on nitroglycerin-induced attacks in cluster headache. *Cephalgia.* 2000;20(2):85–91.
 - 36. Andersson PG, Jespersen LT. Dihydroergotamine nasal spray in the treatment of attacks of cluster headache. A double-blind trial versus placebo. *Cephalgia.* 1986;6(1):51–4.
 - 37. Mather PJ, Silberstein SD, Schulman EA, et al. The Treatment of Cluster Headache With Repetitive Intravenous Dihydroergotamine. *Headache J Head Face Pain.* 1991;31(8):525–32.
 - 38. Matharu MS, Levy MJ, Meeran K, et al. Subcutaneous octreotide in cluster headache: Randomized placebo-controlled double-blind crossover study. *Ann Neurol.* 2004;56(4):488–94.
 - 39. Levy MJ, Matharu MS, Meeran K, et al. The clinical characteristics of headache in patients with pituitary tumours. *Brain.* 2005;128(8):1921–30.
 - 40. Robbins MS, Starling AJ, Pringsheim TM, et al. Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines. *Headache.* 2016;56(7):1093–106.
 - 41. Leone M, D'Amico D, Frediani F, et al. Verapamil in the prophylaxis of episodic cluster headache: A double-blind study versus placebo. *Neurology.* 2000;54(6):1382–5.
 - 42. Blau JN, Engel HO. Individualizing treatment with verapamil for cluster headache patients. *Headache.* 2004;44(10):1013–8.
 - 43. Lee Peterlin B, Allan Purdy R, Rapoport AM. Acute and preventive pharmacologic treatment of cluster headache. *Neurology.* 2011;77(9):921.
 - 44. Cohen AS, Matharu MS, Goadsby PJ. Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. *Neurology.* 2007;69(7):668–75.
 - 45. Ashkenazi A, Schwedt T. Cluster headache-acute and prophylactic therapy. *Headache.* 2011;51(2):272–86.
 - 46. Förderreuther S, Mayer M, Straube A. Authors' Reply: Treatment of Cluster Headache with Topiramate: Effects and Side-Effects in Five Patients. *Cephalgia.* 2003;23(1):70.



47. Leone M, Dodick D, Rigamonti A, et al. Topiramate in cluster headache prophylaxis: An open trial. *Cephalalgia*. 2003;23(10):1001–2.
48. El Amrani M, Massiou H, Bousser MG. A negative trial of sodium valproate in cluster headache: Methodological issues. *Cephalalgia*. 2002;22(3):205–8.
49. Ambrosini A, Vandenheede M, Rossi P, et al. Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: A double-blind placebo-controlled study. *Pain*. 2005;118(1–2):92–6.
50. Leroux E, Valade D, Taifas I, et al. Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: A randomised, double-blind, placebo-controlled trial. *Lancet Neurol*. 2011;10(10):891–7.
51. Felisati G, Arnone F, Lozza P, et al. Sphenopalatine endoscopic ganglion block: A revision of a traditional technique for cluster headache. *Laryngoscope*. 2006;116(8):1447–50.
52. Gaul C, Diener HC, Silver N, et al. Non-invasive vagus nerve stimulation for PREVENTion and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study. *Cephalgia*. 2016;36(6):534–46.
53. Schoenen J, Jensen RH, Lantéri-Minet M, et al. Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: A randomized, sham-controlled study. *Cephalgia*. 2013;33(10):816–30.
54. Miller S, Sinclair AJ, Davies B, et al. Neurostimulation in the treatment of primary headaches. *Pract Neurol*. 2016;16(5):362–75.
55. Magis D, Gerard PY, Remacle JM, et al. Sustained effectiveness of occipital nerve stimulation in drug-resistant chronic cluster headache. *Headache*. 2011;51(8):1191–201.
56. Magis D, Allena M, Bolla M, et al. Occipital nerve stimulation for drug-resistant chronic cluster headache: a prospective pilot study. *Lancet Neurol*. 2007;6(4):314–21.
57. Leone M, Franzini A, Bussone G. Stereotactic Stimulation of Posterior Hypothalamic Gray Matter in a Patient with Intractable Cluster Headache. *N Engl J Med*. 2001;345(19):1428–9.
58. Magis D, Schoenen J. Advances and challenges in neurostimulation for headaches. *Lancet Neurol*. 2012;11(8):708–19.
59. Goadsby PJ, Dodick DW, Leone M, et al. Trial of Galcanezumab in Prevention of Episodic Cluster Headache. *N Engl J Med*. 2019;381(2):132–41.
60. Dodick DW, Goadsby PJ, Lucas C, et al. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment. *Cephalgia*. 2020;40(9):935–48.
61. Chan C, Goadsby PJ. CGRP pathway monoclonal antibodies for cluster headache. *Expert Opin Biol Ther*. 2020;20(8):947–53.